ZURICH, April 29 (Reuters) - Novartis AG said 80-83 percent of those taking its multiple sclerosis drug FTY720 are relapse-free compared with 69 percent on the leading current treatment, but it ...

Novartis won approval for its multiple sclerosis drug Mayzent, which will launch at a price of $88,000 annually, according to Reuters. 1. Mayzent, an oral drug, was approved for adults with relapsing ...

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed. The case further ...

Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya ® (fingolimod) vs. interferon beta-1a, in children and adolescents ...

ZURICH (Reuters) - Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with ...

The FDA approved Dec. 5 three applications for the first generic versions of Gilenya, Novartis’ drug designed to treat adults with relapsing forms of multiple sclerosis. The approvals were granted to ...

ZURICH (Reuters) - Novartis's investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi's Aubagio as the Swiss drugmaker ...

LONDON (MarketWatch) -- Novartis and Bayer on Monday inked a pact on multiple sclerosis drugs that will see Bayer assist Novartis in winning approval for the FTY720 oral once-daily therapy that's ...

(Reuters) - A federal judge on Tuesday dismissed, for the second time, a whistleblower lawsuit accusing drugmaker Novartis AG of paying kickbacks to doctors through a sham speaker program to promote ...